Advancing the science of ventilator-associated pneumonia surveillance by Klompas, Michael
 




(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Klompas, Michael. 2012. “Advancing the science of ventilator-
associated pneumonia surveillance.” Critical Care 16 (5): 165.
doi:10.1186/cc11656. http://dx.doi.org/10.1186/cc11656.
Published Version doi:10.1186/cc11656
Accessed February 19, 2015 2:42:16 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11878922
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAATh   e report by Bénet and colleagues in the previous issue 
of Critical Care is at once a welcome reminder of the 
pivotal importance of infection surveillance programs 
and a window into current weaknesses in surveillance 
science that threaten the credibility and utility of infec-
tion control programs [1]. Bénet and colleagues assessed 
the impact of a one-year lapse in surveillance in a 
medical–surgical ICU (surveillance stopped because the 
infection preventionist charged with supporting the unit 
became burned out – evidence, perhaps, of the under-
resourcing of infection control programs). Ventilator-
associated pneumonia (VAP) rates rose from 13.4 VAP 
cases/1,000 ventilator-days in the 3 years prior to surveil-
lance interruption to 22.9 VAP cases/1,000 ventilator-
days in the 3 years following surveillance interruption. In 
addition, the average duration of mechanical ventilation 
rose from 7.7 days to 11.3 days (P = 0.007) and hospital 
mortality rose from 13.5% to 18.8% (P = 0.028). VAP rates 
and mortality rates were stable, by contrast, in a parallel 
medical unit that enjoyed continuous surveillance and 
infection control support throughout the study period.
Bénet and colleagues’ ﬁ   ndings echo the seminal 
conclusions of the Study of the Eﬃ   cacy of Nosocomial 
Infection Control (SENIC) published by the Centers for 
Disease Control and Prevention in 1985 [2]. Th  e  SENIC 
project took advantage of a natural experiment: US 
hospitals began establishing infection control programs 
of varying intensities starting in the early 1970s. SENIC 
investigators reviewed approximately 338,000 patient 
charts from 338 representative US hospitals and com-
pared hospital-acquired infection rates in 1970 versus 
those in 1976. Th  e investigators also characterized the 
intensity of surveillance and infection prevention activi-
ties in each hospital and then measured the association of 
each with changes in infection rates [3]. After adjusting 
for changes in population risk proﬁ  les, average lengths of 
stay, nurse-to-patient ratios, and other factors, SENIC 
investigators found that high-intensity infection surveil-
lance and prevention programs reduced hospital infec-
tion rates by 32% while infection rates rose by 18% in 
hospitals without infection control programs [2].
Th  e SENIC project cost $27 million and took over a 
decade to complete but it deﬁ   nitively established the 
importance of infection surveillance and control pro  grams. 
Th  e infection surveillance and reporting land  scape has 
changed considerably, however, in the 27  years since 
SENIC was published. Public reporting, benchmarking, 
and pay for performance movements have focused con-
siderable attention upon hospitals’ VAP rates and thereby 
generated powerful incentives for hospitals to make their 
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The landmark Study on the Effi   cacy of Nosocomial 
Infection Control defi  nitively demonstrated that 
infection surveillance and control programs prevent 
hospital-acquired infections. The rise of public 
reporting, benchmarking, and pay for performance 
movements, however, has considerably changed 
the infection surveillance landscape in the 27 years 
since this study was published. Clinically nuanced 
surveillance defi  nitions that served the profession well 
for many years have fallen into disfavor because their 
complexity and subjectivity allow for conscious and 
subconscious gaming. These limitations make it very 
diffi   cult to determine whether changes in surveillance 
rates represent true changes in disease incidence or 
artifacts of defi  nition subjectivity, external reporting 
pressures, and internal biases. Surveillance defi  nitions 
need to be revised to enhance objectivity and to 
ensure that they detect clinically meaningful events 
associated with compromised outcomes. The US 
Centers for Disease Control and Prevention recently 
released modifi  ed defi  nitions for ventilator-associated 
events that have the potential to make safety 
surveillance for ventilated patients more credible and 
useful once again.
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colleagues’ study helps illuminate current weaknesses in 
VAP surveillance science that are begin  ning to be addressed 
by the Centers for Disease Control and Prevention.
Bénet and colleagues made a valiant attempt to adjust 
for changes in patient mix and severity of illness over 
time, including factors such as age, gender, immuno-
suppression, antibiotics on ICU admission, and SAPS II 
score on ICU admission. Nonetheless, the dramatic rise 
in patients’ average duration of mechanical ventilation 
and mortality following surveillance interruption raises 
the possibility of important residual diﬀ  erences in patient 
characteristics that may better account for the observed 
jump in VAP rates than surveillance interruption alone. 
Higher VAP rates alone are probably not suﬃ   cient to 
account for the 3.6-day increase in average duration of 
mechanical ventilation and the 39% increase in hospital 
mortality following surveillance interruption since the 
relative rarity of VAP tends to limit its impact on 
population-level outcomes. Bénet and colleagues ob-
served a net increase of 9.3 VAP cases/100 patients: the 
attributable duration of mechanical ventilation for VAP 
would have to be about 40 days to increase the average 
duration of mechanical ventilation for the entire 
population by the observed 3.6 days. Th  is prediction is 
almost eight times the additive duration of mechanical 
ventilation typically associated with VAP [5]. Alterna-
tively or additionally, surveil  lance interruption may have 
led to a drop in the fre  quency of preventive care 
procedures aﬀ  ecting all patients, such as daily sedative 
interruptions and spon  taneous breathing trials that could 
account for the observed changes in population-level 
outcomes as well as the increase in VAP rates [6]. 
Unfortunately, however, Bénet and colleagues did not 
present data on preventive care patterns so it is not 
possible to disentangle the relative contributions of 
changes in case mix, care patterns, and complication 
rates towards their patients’ ultimate outcomes.
Bénet and colleagues’ observed rise in VAP rates 
following surveillance interruption is also complicated by 
the strong possibility of observer bias. VAP surveillance 
is highly subjective. Th  e study VAP deﬁ  nition included 
criteria such as ‘lung inﬁ   ltrates’, ‘sputum modiﬁ  cation’, 
‘suggestive auscultation’, ‘low oxyhaemoglobin saturation’, 
and ‘increased pulmonary oxygen consumption’. VAP 
deﬁ  nitions typically do not include concrete guidance on 
interpreting these criteria; rather, surveyors apply the 
criteria using their own discretion. Given that this was a 
retrospective study and infection surveyors were not 
blinded to unit identities, surveyors’ conscious or sub-
conscious expecta  tions regarding VAP rates in a unit that 
foreswore infec  tion surveillance activities for a year may 
have inﬂ  uenced their interpretations. Furthermore, the 
surveyor who resumed surveillance in the target unit 
following inter  ruption was not the same person res  pon-
sible for surveil  lance prior to interruption. Diﬀ  erent 
observers’ VAP assessments in a common population can 
vary by a factor of two or more [7]. We cannot know how 
much the increase in VAP following surveillance 
interruption was due to the change in surveillance 
personnel and diﬀ  erent subjective assess  ments (perhaps 
inﬂ  uenced by sub  con  scious expectations) versus a bona 
ﬁ  de rise in invasive pneumonias.
As Bénet and colleagues’ study demonstrates, the 
problems of patient-mix adjustment and observer bias 
threaten to undermine the credibility of infection surveil-
lance reports [8,9]. Cognizant of these concerns, the 
Centers for Disease Control and Prevention recently 
proposed a new surveillance paradigm for ventilator-
asso  ciated events that is designed to make surveillance 
objec  tive, more reproducible, and potentially auto  matable 
in hospitals with comprehensive electronic health 
records [10,11]. Th   e new paradigm shifts the emphasis of 
surveillance from pneumonia in particular to ventilator-
associated complications (VACs) in general. VACs are 
deﬁ  ned quantitatively on the basis of sustained increases 
in daily minimum positive end-expiratory pressure or 
fraction of inspired oxygen after at least two calendar 
days of stable or improving settings. Early work has 
shown VAC to be an independent predictor of increased 
length of stay and increased hospital mortality [12,13]. 
Subdeﬁ   nitions seek to classify VACs into infection-
related events and possible and probable pneumonias on 
the basis of temper  ature changes, white blood cell counts, 
antibiotic prescribing, quantity of neutrophils on 
pulmonary speci  men Gram stains, and culture results. 
Th  e new surveil  lance deﬁ  nitions do not yet incorporate 
criteria for case-mix adjustments but this has been 
identiﬁ  ed as an area for active research in the future. For 
the present, however, these deﬁ  nitions have the potential 
to make surveillance more objective and eﬃ   cient.
Bénet and colleagues’ study is a valuable reminder of 
the potential risk associated with under-resourcing 
infection surveillance and control programs. Better 
surveillance deﬁ  nitions and better case-mix adjustment 
protocols will help to enhance the credibility and impact 
of their important message.
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